Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.
AL001 is being developed as an oral lithium-based therapy and has the potential to deliver lithium carbonate to the brain while mitigating or avoiding current toxicities associated with lithium.
“Advancing AL001 into a phase 2A clinical trial as planned marks an important milestone for Alzamend,” Alzamend CEO Stephan Jackman said in a released statement. “We are one step closer to proving that AL001 could potentially provide clinicians with